Outcomes of natural cycles versus programmed cycles for 1677 frozen-thawed embryo transfers.
The study compares outcomes for patients with frozen embryos who had frozen-thawed embryo transfer (FET) timed to their natural ovulation cycle versus cycles in which endometrial timing was programmed with oestrogen and progesterone. A total of 1205 patients undergoing 1677 FET cycles between 1 January 2000 and 31 December 2006 were analysed. Comparisons were made for patients undergoing modified natural versus programmed FET cycles, as well as between patients using their own eggs for frozen embryos versus those using donor-egg-derived embryos. Clinical pregnancy (gestational sac on 7 week ultrasound) rates (CPR), as well as miscarriage rates, were significantly higher in programmed FET cycles in patients using their own eggs (106/262, 40.5% per embryo transfer, P = 0.015) However, there was not a difference in delivered pregnancies between cycle types in own egg patients (natural cycle delivery rate 245/862, 28.4%; programmed cycle delivery rate 77/262, 29.4%). Furthermore, CPR were not different in natural (38/129, 29.5%) versus programmed cycles (144/424, 34.0%) for ovum donor recipients, nor were delivered pregnancy rates different in natural (33/129, 25.6%) versus programmed cycles (114/424, 26.9%) for ovum donor recipients. In conclusion, there is no significant difference in delivery rates for FET in natural (278/991, 28.1%) versus programmed (191/686, 27.8%) cycles using both own embryos and donor-egg-derived embryos.
Givens
Carolyn R
CR
Pacific Fertility Center, San Francisco, California, USA. info@pacifcfertility.com
Markun
Leslie C
LC
Ryan
Isabelle P
IP
Chenette
Philip E
PE
Herbert
Carl M
CM
Schriock
Eldon D
ED
D000022:Abortion, Spontaneous / Q000453:epidemiology / Q000209:etiology; D000328:Adult; D036861:Delivery, Obstetric / Q000706:statistics & numerical data; D004624:Embryo Transfer / Q000379:methods*; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005615:Freezing / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D008597:Menstrual Cycle / Q000187:drug effects / Q000502:physiology; D010062:Ovulation Induction / Q000009:adverse effects; D011247:Pregnancy; D018873:Pregnancy Rate; D011374:Progesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D027724:Reproductive Techniques, Assisted; D013997:Time Factors; D014019:Tissue Donors; D016896:Treatment Outcome
D004967:Estrogens; D005300:Fertility Agents, Female; D011374:Progesterone